BioXcel Therapeutics, Inc. Insider Trading

BTAI

Last 12 months

Insiders sold 43K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Aug 2019.

Net open-market

−43K

0 buys · 4 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Aug 2019

Aug 23, 2019

Get an email when BTAI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 20	Frank Yocca Chief Scientific Officer	Sold10b5-1 plan	6,845	$1.09	7K	21%	Form 4
May 20	Javier Rodriguez See Remarks	Sold10b5-1 plan	6,560	$1.08	7K	20%	Form 4
May 20	Richard I Steinhart Chief Financial Officer	Sold10b5-1 plan	6,845	$1.09	7K	21%	Form 4
May 20	Vimal Mehta CEO and President	Sold10b5-1 plan	19,419	$1.09	21K	3.4%	Form 4
Dec 16, 2024	Vincent O'Neill See Remarks	Sold10b5-1 plan	165	$0.35	$58	0.8%	Form 4
Dec 16, 2024	Vimal Mehta CEO and President	Sold10b5-1 plan 2 parts	3,117	$0.36 average	1K	<0.1%	Form 4
Dec 16, 2024	Richard I Steinhart Chief Financial Officer	Sold10b5-1 plan 2 parts	577	$0.36 average	$208	2.7%	Form 4
Dec 16, 2024	Javier Rodriguez See Remarks	Sold10b5-1 plan 2 parts	430	$0.36 average	$155	1.7%	Form 4
Dec 16, 2024	Frank Yocca Chief Scientific Officer	Sold10b5-1 plan 2 parts	430	$0.35 average	$153	1.5%	Form 4

May 2010b5-1 plan
Frank Yocca
Chief Scientific Officer · sold 6,845 at $1.09
7K
21% of stake
May 2010b5-1 plan
Javier Rodriguez
See Remarks · sold 6,560 at $1.08
7K
20% of stake
May 2010b5-1 plan
Richard I Steinhart
Chief Financial Officer · sold 6,845 at $1.09
7K
21% of stake
May 2010b5-1 plan
Vimal Mehta
CEO and President · sold 19,419 at $1.09
21K
3.4% of stake
Dec 16, 202410b5-1 plan
Vincent O'Neill
See Remarks · sold 165 at $0.35
$58
0.8% of stake
Dec 16, 202410b5-1 plan
Vimal Mehta
CEO and President · sold 3,117 at avg $0.36
1K
<0.1% of stake
Dec 16, 202410b5-1 plan
Richard I Steinhart
Chief Financial Officer · sold 577 at avg $0.36
$208
2.7% of stake
Dec 16, 202410b5-1 plan
Javier Rodriguez
See Remarks · sold 430 at avg $0.36
$155
1.7% of stake
Dec 16, 202410b5-1 plan
Frank Yocca
Chief Scientific Officer · sold 430 at avg $0.35
$153
1.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BTAI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BTAI

CompareIntrinsic value

SCNXScienture Holdings Inc.

$3.42-0.87%0

ONCOOnconetix Inc.

$0.66+15.69%50

RLYBRallybio Corporation

$15.90+0.25%62

SLNSilence Therapeutics plc

$19.80+0.10%10

VCNXVaccinex, Inc.

$0.70-1.39%10

ELABPMGC Holdings Inc.

$1.92-1.03%20

QUCYQuantum Cyber N.V.

$0.74+2.62%10

LIPOLipella Pharmaceuticals Inc.

$0.00+0.00%25

Spot a number that looks wrong? Check it in BTAI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BTAI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.